Advanced Filters
noise

Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 145 clinical trials
G Grégory PUGNET, MD

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this …

18 years of age All Phase 2
J Jeffrey Y. Wong

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

This early phase I trial studies the side effects and feasibility of total body irradiation using intensity modulation radiation therapy (IMRT) when given in combination with cyclophosphamide prior to stem cell transplant to treat severe systemic sclerosis. IMRT delivers total body radiation therapy more precisely and may reduce radiation exposure …

18 - 65 years of age All Phase 0

RY_SW01 Cell Injection Therapy in Systemic Sclerosis

Systemic sclerosis (SSc) tends to progress to involve multiple vital organs within 5 years of diagnosis, significantly impacting patient prognosis and survival. Clinical indications suggest that early intervention is more favorable for long-term outcomes in patients. Although guidelines recommend various drugs for symptomatic treatment, there is currently no standard therapy …

18 - 65 years of age All Phase 1/2
C Chadwick Prodromos, M.D.

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis

years of age All Phase 1

Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis

The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune …

18 years of age All Phase N/A
C Chloé STAVRIS, MD

Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients

Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could contribute to the pathophysiology of systemic autoimmune diseases such as Systemic Sclerosis (SCS). A future …

18 years of age All Phase N/A
周胜男

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in …

10 - 65 years of age All Phase 1/2

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.

18 - 65 years of age All Phase 1
Q Qiubai Li, Professor

The Clinical Study on the Treatment of SSc With UTAA91 Injection.

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

18 years of age All Phase 0
P Paul DECKER, MD

Evaluation of Muscle Involvement in Systemic Sclerosis

Muscle involvement is poorly described in patients with systemic sclerosis (SSc) . The prevalence of muscle damage is evaluated at 5-95 % of SSc patients, particularly due to variable definitions depending on the series in the scientific litterature. Muscle clinicobiological and histological presentation an response to immunosuppressive treatments are highly …

18 years of age All Phase N/A

Simplify language using AI